Cencora's Specialty Supply Chain: Where COR's Growth Is Headed
COR bets on MSOs, specialty logistics and AI tools to deepen ties beyond distribution???even as GLP-1 mix and pricing swings cloud results.
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue?
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know
The mean of analysts' price targets for Cencora (COR) points to a 33.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Cencora, Inc. (COR) Presents at BofA Securities 2026 China Conference Transcript
Cencora, Inc. (COR) Presents at BofA Securities 2026 China Conference Transcript
Cencora, Inc. (COR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Cencora, Inc. (COR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Why Cencora (COR) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cencora Q2 Earnings Call Highlights
Cencora NYSE: COR reported higher fiscal second-quarter adjusted earnings and operating income, while management raised its full-year adjusted EPS outlook and said it would resume opportunistic share repurchases. The pharmaceutical distribution and healthcare services company also lowered its full-year revenue growth expectations, citing faster-than-anticipated brand conversions at a large mail-order pharmacy customer and slower expected growth in GLP-1 products.
Cencora Earnings Review: The Selloff Was Overdone In My View
Cencora reported Q2 results with 3.8% revenue growth and a 129% EPS increase, but shares fell sharply, apparently due to a revenue miss. Despite a forward P/E of ~14 and manageable debt, COR faces thin margins, client concentration risks, and headwinds from biosimilars and drug price reductions. Management remains confident, targeting $3B in free cash flow and $1B in share repurchases for 2026, with ongoing M&A to expand specialty services.
Cencora, Inc. (COR) Q2 2026 Earnings Call Transcript
Cencora, Inc. (COR) Q2 2026 Earnings Call Transcript
COR Stock Falls on Q2 Earnings & Revenue Miss, FY26 EPS View Raised
Cencora shares sink after Q2 earnings and revenues miss estimates, even as the company raises its fiscal 2026 EPS outlook.
Cencora (COR) Misses Q2 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $4.75 per share, missing the Zacks Consensus Estimate of $4.8 per share. This compares to earnings of $4.42 per share a year ago.
